David DiGiusto

David L. DiGiusto, PhD, Executive Director, Stem Cells and Cellular Therapeutics Operations, Stanford Healthcare; Senior Research Scientist, Division of Pediatric Stem Cell Transplantation and Regenerative Medicine, Stanford University School of Medicine

 

Research Description: Dr. DiGiusto joined Stanford in 2015 and has over 20 years of experience in the scientific, clinical and regulatory aspects of cells as therapeutic agents including the isolation, characterization and genetic modification of hematopoietic stem cells and T-cells for clinical applications, including diabetes. Over the past 20 years, including 18 years at the Beckman Research Institute of the City of Hope prior to joining Stanford in 2015, he collaboratively created four GMP-compliant biologics manufacturing facilities and associated quality systems, production and quality-control testing programs, including human islet isolation in the context of the NIH-funded Integrated Islet Distribution Program (IIDP). Under his direction, plasmid DNA, T-cells and gene-modified hematopoietic stem cell products have been manufactured and released for use in Phase I/II clinical trials at City of Hope and collaborating institutions. His laboratory at Stanford (The Laboratory for Cell and Gene Medicine) specializes in the development of manufacturing processes and quality-control assays and provides clinical production and regulatory support activities for investigational cell products. Together with Stanford DRC members, including Drs. Kim, Meyer, Visser, Thakor, Maahs, Kraemer and Park, he is working to establish autologous and allogeneic human islet transplantation programs at Stanford Healthcare.

Selected relevant publications (Stanford DRC members in BOLD):

1.     Luo D, Smith JA, Meadows NA, Schuh A, Manescu KE, Bure K, Davies B, Horne R, Kope M, DiGiusto DL, Brindley DA. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics. Front Genet 6:357, 2016.

 

2.     Li L, Torres-Coronado M, Gu A, Rao A, Gardner AM, Epps EW, Gonzalez N, Tran CA, Wu X, Wang JH, DiGiusto DL. Enhanced genetic modification of adult growth factor mobilized peripheral blood hematopoietic stem and progenitor cells with rapamycin. Stem Cells Transl Med 3:1199-208, 2014.

 

3.     Gu A, Torres-Coronado M, Tran CA, Vu H, Epps EW, Chung J, Gonzalez N, Blanchard S, DiGiusto DL. Engraftment and lineage potential of adult hematopoietic stem and progenitor cells is compromised following short-term culture in the presence of an aryl hydrocarbon receptor antagonist. Hum Gene Ther Methods 25:221-31, 2014.

 

4.     DiGiusto, DL and H-P Kiem. Current Translational Practices in Hematopoietic Cell and Gene Therapy. Cytotherapy 14:775-90, 2012.

 

5.     Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ. Anti-Transgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Re-directed T Cells in Humans, Biology of Blood and Marrow Transplantation16:1245-56, 2010.